Depression: A Global Public Health Concern

Marcus, Mildred Rendl; Mt, Yasamy; Chisholm, Daniel; Saxena, Sumit; Yasamy, M. Taghi; m, Van Ommeren; Ommeren, Mark van; Chrisholm, D. J

doi:10.1037/e517532013-004

Cited by 559 publications

(423 citation statements)

References 0 publications

Supporting

Mentioning

393

Contrasting

Unclassified

Order By: Relevance

“…Also carriers of the C allele represented 3.3 fold better response to sertraline comparing with other variants (P=0.001, OR=3.3; 95%CI=1.72-6.50). While world-wide rate of depression is rapidly increasing (36), response to antidepressants and remission is fairly satisfactory (37). Although many studies bold the contribution of genetics in predisposition to MDD, its role as therapeutic determinant remains obscure.…”

Section: Discussionmentioning

confidence: 99%

Beta Adrenoceptor Polymorphism and Clinical Response to Sertraline in Major Depressive Patients

et al. 2017

View full text Add to dashboard Cite

-Purpose: The adrenoceptor family, as one of the main contributors in regulating the noradrenergic system, has been studied in involvement of depression and its treatment. A functional polymorphism of G1165C on beta adrenoceptor (βAR) enhances post receptor signalling and is assumed to be involved in pharmacotherapy of depression. The aim of the present study was to discern the influence of G1165C polymorphism in the β1AR gene on individual differences in response to sertraline. Methods: One hundred newly diagnosed patients completed 6 weeks of sertraline treatment. Response to treatment was defined as a 50% decrease in Hamilton Rating Scale for depression (HRSD). Results: The patients who carried CC genotype responded five times more to sertraline comparing with other variants (P=0.005; OR=5.7; 95%CI=1.4-23.9). Moreover, carriers of C allele responded three times more to sertraline than patients with the G allele (P=0.001; OR= 3.3; 95%CI= 1.72-6.50). Conclusion:In conclusion, our results support the hypothesis that genetic variation of β1AR might influence clinical response to sertraline.

show abstract

Section: Discussionmentioning

confidence: 99%

Beta Adrenoceptor Polymorphism and Clinical Response to Sertraline in Major Depressive Patients

et al. 2017

View full text Add to dashboard Cite

show abstract

“…We assume that the paralysis of the injected frown muscles interrupts a proprioceptive feedback loop from the face to the emotional brain, therefore reducing the ability to feel negative emotions [15][16][17]. In depression, there is a Introduction ▼ Affecting more than 350 million individuals worldwide, depression is one of the greatest medical challenges of our time [1]. There are several effective psychotherapeutic, pharmacological, and somatic options for the treatment of depression, but still a considerable proportion of patients do not attain remission.…”

mentioning

confidence: 99%

Treating Depression with Botulinum Toxin: A Pooled Analysis of Randomized Controlled Trials

Magid

Finzi²,

Krüger

et al. 2015

Pharmacopsychiatry

View full text Add to dashboard Cite

Introduction: Botulinum toxin A (BTA) injection into the glabellar region is currently being studied as a treatment for major depressive disorder (MDD). Here we explore efficacy data of this novel approach in a pooled analysis. Methods: A literature search revealed 3 RCTs on this topic. Individual patient data and clinical end points shared by these 3 trials were pooled and analyzed as one study (n=134) using multiple regression models with random effects. Results: In the pooled sample, the BTA (n=59) and the placebo group (n=75) did not differ in the baseline variables. Efficacy outcomes revealed BTA superiority over placebo: Improvement in the Hamilton Depression Rating Scale or Montgomery-Asberg Depression Rating Scale 6 weeks after baseline was 45.7% for BTA vs. 14.6% for placebo (p<0.0001), corresponding to a BTA response rate of 54.2% (vs. 10.7%) and a BTA remission rate of 30.5% (vs. 6.7%). Discussion: Equalling the status of a meta-analysis, this study increases evidence that a single treatment of BTA into the glabellar region can reduce symptoms of MDD. Further studies are needed to better understand how BTA exerts its mood-lifting effect.

show abstract

“…7 Economic analysis has indicated that treating depression in primary care is feasible, affordable and cost-effective. These results indicate the urgency of addressing depression as a public-health priority to reduce disease burden and disability, and to improve the overall health of populations.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of depression among hypertensive individuals in urban Trivandrum: a cross sectional study

Prathibha

Varghese

Dev

et al. 2017

Int J Community Med Public Health

View full text Add to dashboard Cite

Background: People with chronic diseases are more likely to have depression than those without any physical illness. Lack of adherence to treatment, poor compliance to life style modification therapy and lost to follow up are major concerns raised in the management of hypertension among subjects with co-morbid depression. Hence it is very important to explore the epidemiology of depression among hypertensives. Methods: The study was conducted in Medical College health unit area of urban Trivandrum as a cross sectional survey among adults >18 years who were diagnosed to have hypertension. The subjects were interviewed using a semi structured questionnaire to collect the socio-demographic variables and the 9 item Patient Health Questionnaire (PHQ 9) to capture depression. Data from a sample of 432 hypertensive individuals collected were analyzed and Chi square, t test, was done to find the associated factors. Results: Mean age of the study subjects was 62.47 years. Among the study subjects the blood pressure was under control among only 33.8% of the study population. The prevalence of depression was found to be 33.3% (144) with 95% C.I (27.98-39.14). Gender, Socio economic status, marital status, low educational status, regular physical activity, duration of hypertension, uncontrolled BP, were found to be significantly associated with depression. Conclusions: The prevalence of depression among hypertensive individuals is high in this study population. Adequate control of BP along with awareness among primary care physicians in identifying those with hypertension and co-morbid depression is essential.

show abstract

Depression: A Global Public Health Concern

Cited by 559 publications

References 0 publications

Beta Adrenoceptor Polymorphism and Clinical Response to Sertraline in Major Depressive Patients

Beta Adrenoceptor Polymorphism and Clinical Response to Sertraline in Major Depressive Patients

Treating Depression with Botulinum Toxin: A Pooled Analysis of Randomized Controlled Trials

Prevalence of depression among hypertensive individuals in urban Trivandrum: a cross sectional study

Contact Info

Product

Resources

About